# CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma

> **NCT06605833** · — · ENROLLING_BY_INVITATION · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma Stage III or IV

## Interventions

- **DIAGNOSTIC_TEST:** 12-Lead ECG
- **DIAGNOSTIC_TEST:** Transthoracic Echocardiogram
- **DIAGNOSTIC_TEST:** Cardiac MRI
- **DIAGNOSTIC_TEST:** Cardiac Biomarker Screening
- **OTHER:** Basic Observations

## Key facts

- **NCT ID:** NCT06605833
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-26
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06605833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06605833, "CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06605833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*